New indication for BRIVIACT(R) (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults

BRIVIACT® CV provides a new monotherapy treatment option for epilepsy patients 16 years of age and older with partial-onset (focal) seizures, which can be initiated at a therapeutic dose at day one Approval applies a newly established regulatory pat... Biopharmaceuticals, Neurology, FDA UCB, BRIVIACT, brivaracetam, epilepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news